APART Advanced Profiling of Anti-Rheumatic Therapies

Centocor Ortho Biotech

Status and phase: Completed; Phase 4

Conditions: Arthritis, Rheumatoid

Treatments: Procedure: Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.

Study type: Interventional

Funder types: Industry

Identifiers

NCT00378261

CR004807

Details and patient eligibility

About

The purpose of this study is to evaluate the utility of an electronic data capture system (EDCS) in a rheumatology clinical practice setting and to assess the impact of this system on patient satisfaction with patient-physician interaction.

Full description

This is a randomized, multicenter observational study to assess the impact of the EDCS in a rheumatology clinical practice setting on patient satisfaction with patient-physician communication using the Health Tracker electronic data capture system . Patients will be randomly assigned in a 2:1 ratio to the Health Tracker-user or non-user groups, respectively. The primary outcomes of this study will be the impact that information gathered and analyzed by an electronic data capture system has on patient satisfaction with arthritis care and patient physician interactions in clinical practice. Patient satisfaction will be assessed using a questionnaire developed specifically for this study.

This study does not involve the use of any investigational drugs, and the protocol does not mandate the treatment regimen patients will receive. Physicians will prescribe antirheumatic medications in accordance with usual clinical practice. The planned duration of subject participation is 12 months

Enrollment: 1,079 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with active rheumatoid arthritis according to the revised criteria of the ACR (1987)
• Have rheumatoid arthritis that requires regularly scheduled visits with their rheumatologist at least every 3 months
• Willing and able to adhere to protocol requirements and participate in a study, lasting 12 months

Exclusion criteria

• Patients currently receiving investigational drugs
• Currently participating in other clinical trials or safety registries for rheumatoid arthritis or rheumatoid arthritis -related therapies